Market Cap 6.36B
Revenue (ttm) 7.80B
Net Income (ttm) 169.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 7.74
Profit Margin 2.18%
Debt to Equity Ratio 1.28
Volume 324,700
Avg Vol 488,238
Day's Range N/A - N/A
Shares Out 687.56M
Stochastic %K 89%
Beta 0.67
Analysts Sell
Price Target $11.10

Company Profile

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clo...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 34 935 712 200
Fax: 34 938 008 000
Address:
Avinguda de la Generalitat 152-158, Parque Empresarial Can Sant Joan Sant Cugat del Valles, Barcelona, Spain
SuperGreenToday
SuperGreenToday Jan. 29 at 7:59 PM
$GRFS Share Price: $9.20 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.70 – $0.86 Potential Upside: 74% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 5:28 PM
$GRFS RSI: 52.13, MACD: 0.0563 Vol: 0.18, MA20: 9.16, MA50: 8.91 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 26 at 6:24 PM
$GRFS Current Stock Price: $9.02 Contracts to trade: $9.0 GRFS Jan 16 2026 Call Entry: $0.25 Exit: $0.49 ROI: 94% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ResideRealm
ResideRealm Dec. 26 at 6:05 AM
$GRFS Credibility now depends on repeatable results instead of isolated wins. Cash generation will determine how self-sustaining growth becomes. Sustained momentum may broaden institutional interest. Execution precision is the primary catalyst from here.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 3:49 PM
$GRFS RSI: 55.83, MACD: 0.0457 Vol: 0.15, MA20: 8.93, MA50: 8.97 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 4:08 PM
JP Morgan has adjusted their stance on Grifols ( $GRFS ), setting the rating to Neutral with a target price of 10.3 → 10.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 5 at 11:14 AM
$GRFS Current Stock Price: $8.89 Contracts to trade: $10 GRFS Dec 19 2025 Call Entry: $0.05 Exit: $0.08 ROI: 68% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
topstockalerts
topstockalerts Nov. 27 at 7:32 PM
Grifols has appointed board member Tomás Dagá as vice chairman of Grifols Egypt (GEPD), the joint venture with the Egyptian government to deploy the country’s first full plasma production system for Egypt, Africa, and the Middle East. The project, launched under a 2020 agreement, involves nearly €280 million in investment and aims to secure the national supply of plasma-derived medicines. Grifols currently operates 16 donation centers in Egypt, plans to open four more in 2026, and is establishing an analysis laboratory and a central plasma logistics center. The first phase of the plasma processing plant is set to start operations next year. The initiative has already created around 1,200 high-skilled direct jobs and over 14,000 indirect and induced positions. Dagá will oversee industrial and regulatory consolidation, strengthen relations with Egyptian authorities, and accelerate the full operational rollout of the project. $GRFS
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 7 at 1:03 PM
$RCAT will use the CAT portion of your name for part of the name for project with DON n Puerto Rico isolating R for markets R CELLS $RCEL accessing $CERS $GRFS
1 · Reply
BillionerOfKing
BillionerOfKing Nov. 4 at 12:31 PM
$GRFS Current Stock Price: $9.43 Contracts to trade: $10 GRFS Nov 21 2025 Call Entry: $0.32 Exit: $0.40 ROI: 26% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on GRFS
White Falcon: Q4 2025 Portfolio Positions

Jan 26, 2026, 9:15 PM EST - 7 days ago

White Falcon: Q4 2025 Portfolio Positions

AMD AMZN CSIQ EPAM EPS FNV HUN


Grifols: Positive/Neutral Scenario Posits An Upside

Dec 8, 2025, 12:02 PM EST - 2 months ago

Grifols: Positive/Neutral Scenario Posits An Upside


Grifols, S.A. (GIKLY) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:11 PM EST - 3 months ago

Grifols, S.A. (GIKLY) Q3 2025 Earnings Call Transcript


Top Biotech Stocks Riding The Rally

Nov 4, 2025, 3:15 PM EST - 3 months ago

Top Biotech Stocks Riding The Rally

CTMX GRAL INCY


Grifols: Significant Upside Likely Materializing

Oct 2, 2025, 9:23 PM EDT - 4 months ago

Grifols: Significant Upside Likely Materializing


Grifols: If This Works Out, It Has Massive Upside

May 22, 2025, 12:09 PM EDT - 9 months ago

Grifols: If This Works Out, It Has Massive Upside


Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript

May 12, 2025, 4:51 PM EDT - 9 months ago

Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript


Grifols' sales rise over 10% in 2024, above target

Feb 26, 2025, 12:18 PM EST - 1 year ago

Grifols' sales rise over 10% in 2024, above target


Flat Footed Calls for Prompt Governance Overhaul at Grifols

Dec 10, 2024, 12:23 PM EST - 1 year ago

Flat Footed Calls for Prompt Governance Overhaul at Grifols


Grifols: More Attractive Than In A Very Long Time

Nov 29, 2024, 12:30 PM EST - 1 year ago

Grifols: More Attractive Than In A Very Long Time


Significant Shareholders Exercise Right to Grifols Board Seat

Sep 19, 2024, 3:23 PM EDT - 1 year ago

Significant Shareholders Exercise Right to Grifols Board Seat


SuperGreenToday
SuperGreenToday Jan. 29 at 7:59 PM
$GRFS Share Price: $9.20 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.70 – $0.86 Potential Upside: 74% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 5:28 PM
$GRFS RSI: 52.13, MACD: 0.0563 Vol: 0.18, MA20: 9.16, MA50: 8.91 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 26 at 6:24 PM
$GRFS Current Stock Price: $9.02 Contracts to trade: $9.0 GRFS Jan 16 2026 Call Entry: $0.25 Exit: $0.49 ROI: 94% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ResideRealm
ResideRealm Dec. 26 at 6:05 AM
$GRFS Credibility now depends on repeatable results instead of isolated wins. Cash generation will determine how self-sustaining growth becomes. Sustained momentum may broaden institutional interest. Execution precision is the primary catalyst from here.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 3:49 PM
$GRFS RSI: 55.83, MACD: 0.0457 Vol: 0.15, MA20: 8.93, MA50: 8.97 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 4:08 PM
JP Morgan has adjusted their stance on Grifols ( $GRFS ), setting the rating to Neutral with a target price of 10.3 → 10.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 5 at 11:14 AM
$GRFS Current Stock Price: $8.89 Contracts to trade: $10 GRFS Dec 19 2025 Call Entry: $0.05 Exit: $0.08 ROI: 68% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
topstockalerts
topstockalerts Nov. 27 at 7:32 PM
Grifols has appointed board member Tomás Dagá as vice chairman of Grifols Egypt (GEPD), the joint venture with the Egyptian government to deploy the country’s first full plasma production system for Egypt, Africa, and the Middle East. The project, launched under a 2020 agreement, involves nearly €280 million in investment and aims to secure the national supply of plasma-derived medicines. Grifols currently operates 16 donation centers in Egypt, plans to open four more in 2026, and is establishing an analysis laboratory and a central plasma logistics center. The first phase of the plasma processing plant is set to start operations next year. The initiative has already created around 1,200 high-skilled direct jobs and over 14,000 indirect and induced positions. Dagá will oversee industrial and regulatory consolidation, strengthen relations with Egyptian authorities, and accelerate the full operational rollout of the project. $GRFS
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 7 at 1:03 PM
$RCAT will use the CAT portion of your name for part of the name for project with DON n Puerto Rico isolating R for markets R CELLS $RCEL accessing $CERS $GRFS
1 · Reply
BillionerOfKing
BillionerOfKing Nov. 4 at 12:31 PM
$GRFS Current Stock Price: $9.43 Contracts to trade: $10 GRFS Nov 21 2025 Call Entry: $0.32 Exit: $0.40 ROI: 26% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
etrain2000
etrain2000 Nov. 3 at 1:45 AM
$GRFS Where is everyone hiding! Havent seen yall since earnings!
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 2:31 PM
$GRFS Brilliant piece that captures GRFS's situation perfectly. So if you want to update your understanding of GRFS or get to know GRFS better, this is essential reading. https://beyondspx.com/quote/GRFS/analysis/grifols-nasdaq-grfs-plasma-powerhouse-unleashes-growth-and-deleveraging-momentum
0 · Reply
topstockalerts
topstockalerts Sep. 26 at 5:04 PM
U.S. plans for new pharmaceutical tariffs are seen as negative due to uncertainty but could be an “opportunity” for Grifols, which is fully vertically integrated in the U.S. Banco Sabadell analysts noted the 100% tariff announcement on foreign branded or patented drugs unless companies establish U.S. manufacturing. While the news creates noise, details remain unclear, especially for firms already present in the U.S. Sanofi has announced $ 20B investment in the U.S. through 2030. Grifols is expected to face no negative impact, with ~70% of plasma collection and ~65% of production capacity in the U.S. Analysts see tariffs as a potential advantage for Grifols, the only fully vertically integrated hemoderivatives company in the country. Almirall’s impact would be minimal (~4.5% of sales in the U.S.), and Rovi is unlikely to be affected due to no direct distribution or branded products in the U.S. $GRFS $SNY $ALM $ROVI
0 · Reply
TradeJizzer
TradeJizzer Aug. 14 at 2:18 AM
$GRFS Breaking on X: Grifols just got busted for taking donated blood and selling it. This may gap down in the am.
0 · Reply
Doozio
Doozio Aug. 2 at 6:15 PM
$GRFS dips appears a 🎁 during 🐒🍌🧠⏰♾️
0 · Reply
RunnerSignals
RunnerSignals Jul. 29 at 9:07 PM
$CELC $GRFS $HIMS $ECX $ODP Comeback Kings shook off the midday dips and closed strong
0 · Reply
DonCorleone77
DonCorleone77 Jul. 29 at 5:17 PM
$GRFS Grifols reports Q2 revenue EUR 1.89B vs. EUR 1.79B last quarter -- Q2 profit EUR 191M vs. EUR 115M last quarter. -- Reinstates dividend of EUR 0.15 per share -- Affirms 2025 guidance from capital markets day
0 · Reply
BeefStewart
BeefStewart Jul. 17 at 8:14 PM
$CERS Looks like some plasma-related stocks are just lagging $ADMA $GRFS ....
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 9:07 PM
$GRFS Grifols paid a higher price to buy blood plasma from an entity linked to its controlling family than from third-party suppliers, according to a regulator’s findings submitted in a court case ….
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 24 at 6:59 AM
$GRFS Grifols pagó hasta un 39% más para comprar plasma a Scranton Según las conclusiones de un regulador presentadas en un caso judicial, la farmacéutica española también acordó pagar a Scranton un margen fijo del 16,5% sobre los costes Bad news
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jun. 23 at 8:15 PM
$GRFS bad news ? Weird day
0 · Reply
JarvisFlow
JarvisFlow Jun. 17 at 1:00 PM
JP Morgan updates rating for Grifols ( $GRFS ) to Neutral, target set at 7.6 → 10.3.
0 · Reply